First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trialYuankai Shi, Sheng Hou, Kangsheng Gu et al.|Signal Transduction and Targeted Therapy|2025Cited by 8
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.Zhichao Jiang, Aiping Zhou, Wei Deng et al.|Journal of Clinical Oncology|2022Cited by 0